The headline: a whole new severity taxonomy
This is the first joint de novo PE guideline from basically every society that touches a clot — AHA, ACC, ACCP, ACEP, CHEST, SCAI, SHM, SIR, SVM, and SVN all signed off. The centerpiece is that they scrapped "massive / submassive / low risk" and the ESC four-tier scheme in favor of the AHA/ACC Acute PE Clinical Categories, A through E, each with subcategories, plus an optional R modifier for respiratory failure.
Add "R" if there's hypoxemia, tachypnea, or an oxygen requirement (e.g., C3R, D2R). This maps cleanly onto a treatment algorithm in their Figure 3, which is genuinely the single most useful chart in the document.
Diagnosis: nothing revolutionary
- Wells / Geneva / PERC plus age-adjusted D-dimer and the YEARS algorithm still drive imaging decisions — no change there.
- CTPA still beats V/Q for confirming the diagnosis.
- The one real upgrade: reporting a numerical RV/LV ratio off CTPA is now Class 1, ditching the old subjective eyeball assessment.
- Echo still can't diagnose PE — it's strictly for risk stratification once PE is already confirmed.
Risk stratification
- PESI / Hestia / sPESI are good at finding who's safe to send home (Class 1 for Category A/B).
- Nobody's score reliably predicts who's about to crash — that limitation is stated plainly in the guideline itself.
- Troponin/BNP plus lactate are now Class 1 for anyone Category C or higher.
- RV imaging is Class 1 for Categories C–D.
Management by category
Outpatient territory
Send them home. Initiate a DOAC, done.
Admit and work up
LMWH initiation, biomarkers plus RV imaging. PERT consult is reasonable here.
This is where advanced therapy enters the conversation
Vasopressors (norepinephrine first line) for D2. Evaluate for the "normotensive shock" pattern before it declares itself.
Full advanced-therapy conversation
PERT is Class 1. VA-ECMO for E2. Systemic lysis, CDL, MT, or surgical embolectomy all reasonable at E1.
Advanced therapy: memorize this table, skip the rest
Their own summary table (Table 7) is the single thing worth internalizing. Basically nothing for A–C1. Everything is a shaky 2b — unclear in the C2–D2 zone — this is the exact population enrolled in PEERLESS, which found no mortality or bleeding difference between catheter-directed lysis and mechanical thrombectomy. Things firm up to 2a at E1, where lysis, CDL, MT, and surgery are all reasonable. At E2, it's VA-ECMO plus maybe lysis, and surgery without mechanical support is now Class 3 — no benefit.
| PE Category | Systemic Lysis | Catheter Lysis (CDL) | Mech. Thrombectomy (MT) | Surgical Embolectomy |
|---|---|---|---|---|
| A–C1 | 3–Harm | 3–No Benefit | 3–No Benefit | 3–No Benefit |
| C2 | 3–Harm | 2b — unclear | 2b — unclear | 3–No Benefit |
| C3 | 2b — unclear | 2b — unclear | 2b — unclear | 3–No Benefit |
| D1–D2 | 2b — may consider | 2b — may consider | 2b — may consider | 2b — unclear |
| E1 | 2a | 2a | 2a | 2a |
| E2 | 2a | N/A | N/A | 3–No Benefit |
Anticoagulation highlights
- LMWH over UFH for initial parenteral therapy (Class 1).
- DOAC over VKA for most people (Class 1) — except antiphospholipid syndrome, where VKA is preferred due to arterial thrombosis risk with DOACs.
- Brain tumors: DOAC is now preferred over LMWH to reduce ICH risk — a real flip from older teaching.
- Pregnancy: LMWH/UFH only. DOACs and warfarin are Class 3 harm.
- Extended-phase anticoagulation for unprovoked PE: continue indefinitely. New this cycle — half-dose DOAC (apixaban 2.5 mg BID or rivaroxaban 10 mg daily) is now Class 1 for the extended phase, cutting bleeding without losing efficacy (RENOVE, API-CAT data).
IVC filters
Retrievable over permanent. Pull them as soon as it's safe. Placing one in a patient who's already therapeutically anticoagulated is Class 3 harm.
Anesthesia-relevant callout
There's a dedicated section on sedation and intubation in RV failure. Anything that blunts sympathetic tone — induction agents, positive pressure ventilation — can trigger arrest in a compensated PE patient. Deep sedation and mechanical ventilation are Class 3 harm unless clinically necessary, and if you have to do it, pressors, inotropes, and/or ECMO need to be ready at the bedside first.
Good one to drop at journal club.
CTEPD follow-up
- Ask about dyspnea at every visit for a year.
- Diagnostic workup now requires TTE + a perfusion scan + CPET — no single test rules it out reliably.
- Routine repeat CTPA to check clot resolution is explicitly called out as not useful.
Talking points to sound sharp in the room
- The new A–E taxonomy hasn't been prospectively validated yet — that's listed as the writing committee's own top evidence gap.
- A lot of the advanced-therapy recommendations are still C-LD or B-NR, meaning "reasonable" is doing a lot of work on thin evidence.
- PEERLESS is the trial everyone will bring up — CDL vs. MT, no mortality/bleeding difference, more bailout to alternate therapy in the CDL arm.
- The "normotensive shock" concept (Category D2) is the most clinically interesting new idea — it's trying to catch the patient who looks fine on vitals but is quietly hypoperfusing.